1. Baseline characteristics and enrichment results from the SONAR trial

   Heerspink, H. J. L., Andress, D. L., Bakris, G., Brennan, J. J., Correa-Rotter, R., Hou, F. F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J., Perkovic, V., Tobe, S., Wigderson, M., Yi, T., Parving, H-H. & de Zeeuw, D. Aug-2018 In : Diabetes obesity & metabolism. 20, 8, p. 1829-1835 7 p.

   Research output: Contribution to journal › Article

2. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

   CKD Prognosis Consortium 2018 In : European Heart Journal. 39, 17, p. 1535-1542 8 p.

   Research output: Contribution to journal › Article

3. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease

   Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V. & Heerspink, H. J. L. 23-Jan-2018 In : Nephrology, Dialysis, Transplantation.

   Research output: Contribution to journal › Article

4. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

   CREDENCE Study Investigators 13-Dec-2017 In : American Journal of Nephrology. 46, 6, p. 462-472 11 p.

   Research output: Contribution to journal › Article

5. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

   Heerspink, H. J. L., Andress, D. L., Bakris, G., Brennan, J. J., Correa-Rotter, R., Dey, J., Hou, F. F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J., Perkovic, V., Tobe, S., Wigderson, M., Parving, H-H. & de Zeeuw, D. Jun-2018 In : Diabetes obesity & metabolism. 20, 6, p. 1369-1376 8 p.

   Research output: Contribution to journal › Article

View all (234) »